These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 8253920

  • 1. Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin-releasing hormone agonist/menotrophin in-vitro fertilization cycles.
    Golan A, Herman A, Soffer Y, Bukovsky I, Caspi E, Ron-El R.
    Hum Reprod; 1993 Sep; 8(9):1372-5. PubMed ID: 8253920
    [Abstract] [Full Text] [Related]

  • 2. Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone.
    Claman P, Domingo M, Leader A.
    Hum Reprod; 1992 Apr; 7(4):487-9. PubMed ID: 1522190
    [Abstract] [Full Text] [Related]

  • 3. Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a randomized clinical trial.
    Mochtar MH, Hogerzeil HV, Mol BW.
    Hum Reprod; 1996 Aug; 11(8):1602-5. PubMed ID: 8921100
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization.
    Beckers NG, Laven JS, Eijkemans MJ, Fauser BC.
    Hum Reprod; 2000 Jan; 15(1):43-9. PubMed ID: 10611186
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J, De Vits A, Joostens M, Van Royen E.
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [Abstract] [Full Text] [Related]

  • 8. Effect of disruption versus continuation of gonadotrophin-releasing agonist after human chorionic gonadotrophin administration on corpus luteum function in patients undergoing ovulation induction for in-vitro fertilization.
    Valbuena D, Pellicer A, Guanes PP, Remohí J, Simón C.
    Hum Reprod; 1997 Oct; 12(10):2118-22. PubMed ID: 9402265
    [Abstract] [Full Text] [Related]

  • 9. Gonadotropin Releasing Hormone Agonist Final Oocyte Maturation and Human Chorionic Gonadotropin as Exclusive Luteal Support in Normal Responders.
    Beck-Fruchter R, Baram S, Geslevich Y, Weiss A.
    Gynecol Obstet Invest; 2019 Oct; 84(1):27-34. PubMed ID: 30048969
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a down-regulation protocol and luteal support with progesterone.
    Herman A, Raziel A, Strassburger D, Soffer Y, Bukovsky I, Ron-El R.
    Hum Reprod; 1996 Jul; 11(7):1552-7. PubMed ID: 8671503
    [Abstract] [Full Text] [Related]

  • 13. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.
    Peñarrubia J, Balasch J, Fábregues F, Creus M, Casamitjana R, Ballescá JL, Puerto B, Vanrell JA.
    Hum Reprod; 1998 Dec; 13(12):3315-8. PubMed ID: 9886506
    [Abstract] [Full Text] [Related]

  • 14. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, Thomsen L, Humaidan P.
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG, Erb K, Laursen S, Rasmussen PE, Rex S.
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [Abstract] [Full Text] [Related]

  • 17. Hormonal profiles in successful and unsuccessful implantation in IVF-ET after combined GnRH agonist/gonadotropin treatment for superovulation and hCG luteal support.
    Balasch J, Creus M, Fábregues F, Carmona F, Casamitjana R, Peñarrubia J, Rivera F, Vanrell JA.
    Gynecol Endocrinol; 1995 Mar; 9(1):51-8. PubMed ID: 7793300
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.